Results 21 to 30 of about 23,252 (243)

Fluorine‐Free Poly(ionic Liquid)s Binders for the Aqueous Processing of High‐Voltage NMC811 Cathodes

Advanced Energy & Sustainability Research, 2023
The use of water‐soluble binders enables the transition to more sustainable batteries by the replacement of toxic N‐methyl‐2‐pyrrolidone (NMP) by water.
Ana Clara Rolandi, Cristina Pozo-Gonzalo, Iratxe de Meatza, Nerea Casado, David Mecerreyes, Maria Forsyth   +5 more
doaj   +1 more source

Phosphate Frustration: Treatment Options to Complement Current Therapies

International Journal of Nephrology, 2022
Hyperphosphatemia eventually develops in almost all patients with advanced chronic kidney disease and is associated with negative clinical outcomes. Thus, guidelines recommend targeting treatment to normal phosphate levels in patients with chronic kidney
Pablo E. Pergola
doaj   +1 more source

Fracture risk in chronic kidney disease: A Korean population-based cohort study

Kidney Research and Clinical Practice, 2019
Background : Chronic kidney disease (CKD)-mineral and bone disorder (MBD) and fracture risk are both closely related to declining renal function. Controlling hyperphosphatemia with phosphate binders is a basic principle of CKD-MBD treatment.
Young Eun Kwon, Hyung Yun Choi, Sol Kim, Dong-Ryeol Ryu, Hyung Jung Oh, the ESRD Registry Committee of the Korean Society of Nephrology   +5 more
doaj   +1 more source

Ferric citrate hydrate is associated with a reduced cost of drugs and a smaller change in red blood cell distribution width

Scientific Reports, 2022
The ASTRIO study was a randomised, multicentre, 24-week study that compared the effects of ferric citrate hydrate (FC) and non-iron-based phosphate binders (control) on anaemia management in haemodialysis (HD) patients receiving erythropoiesis ...
Kyoko Ito, Keitaro Yokoyama, Masaaki Nakayama, Masafumi Fukagawa, Hideki Hirakata   +4 more
doaj   +1 more source

Asupan protein dan fosfor, rasio fosfor-protein, dan kadar fosfor darah pada pasien gagal ginjal kronis dengan hemodialisis

Jurnal Gizi Klinik Indonesia, 2012
Background: Hyperphosphatemia has become one of the main causes of death in CKD patients on HD. Thus, correction and prevention of hyperphospatemia is a major component in the management of HD patients.
Ahmad Syauqy, Susetyowati ., Suhardi .
doaj   +1 more source

Proton pump inhibitors may hinder hypophosphatemic effect of lanthanum carbonate, but not of ferric citrate hydrate or sucroferric oxyhydroxide, in hemodialysis patients

Renal Failure, 2020
Because end-stage renal disease patients undergoing hemodialysis frequently take acid suppressants for the treatment or prevention of gastrointestinal diseases, it is important to clarify the drug-interactions between acid suppressants and phosphate ...
Hitoshi Minakuchi, Tadashi Yoshida, Noriko Kaburagi, Teppei Fujino, Sho Endo, Tomoko Yamashita Takemitsu, Norimasa Yamashita, Hiroshi Itoh, Mototsugu Oya   +8 more
doaj   +1 more source

Implementation and effectiveness of an intensive education program on phosphate control among hemodialysis patients: a non-randomized, single-arm, single-center trial

BMC Nephrology, 2021
Background Hyperphosphatemia is a common complication in patients on maintenance hemodialysis. Patients’ adherence to phosphorus control can be improved by consistent education.
Jinmei Yin, Jun Yin, Rongli Lian, Peiqiu Li, Jing Zheng   +4 more
doaj   +1 more source

Interventional study to improve adherence to phosphate binder treatment in dialysis patients

BMC Nephrology, 2019
Background Adherence to phosphate binder treatment is important to prevent high serum phosphate level in chronic dialysis patients. We therefore wanted to investigate patient knowledge, beliefs about and adherence to phosphate binders among these ...
Bodil Jahren Hjemås, Katrine Bøvre, Liv Mathiesen, Jonas Christoffer Lindstrøm, Kathrin Bjerknes   +4 more
doaj   +1 more source

Lanthanum carbonate oral powder: satisfaction, preference and adherence in French and Spanish patients with end-stage renal disease

Drugs in Context, 2016
Background: Phosphate binders, such as lanthanum carbonate, control elevated serum-phosphate levels in patients with end-stage renal disease (ESRD). Lanthanum carbonate is available in oral powder and tablet form.
Michael Keith, Patricia de Sequera, Francois Clair, Riccardo Pedersini   +3 more
doaj   +1 more source

Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). [PDF]

Cochrane Database Syst Rev, 2018
BackgroundPhosphate binders are used to reduce positive phosphate balance and to lower serum phosphate levels for people with chronic kidney disease (CKD) with the aim to prevent progression of chronic kidney disease-mineral and bone disorder (CKD-MBD ...
Ruospo M, Palmer SC, Natale P, Craig JC, Vecchio M, Elder GJ, Strippoli GF.   +6 more
europepmc   +2 more sources